De novo aortic insufficiency during long-term support on a left ventricular assist device: A systematic review and meta-analysis

Salil V. Deo, Vikas Sharma, Yang Hyun Cho, Ishan K. Shah, Soon J. Park

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Aortic insufficiency (AI) may occur while supported on a left ventricular assist device (LVAD). We conducted a systematic review to determine the incidence, predictors, and consequences of AI during LVAD support. MEDLINE was searched for original studies presenting clinical data regarding patients who developed AI during LVAD implant. Seven observational studies (657 patients) were selected for review; 65% of patients underwent implantation with a continuous-flow device (Cf-LVAD). The incidence of AI was 25% (11-42%) (Support period: 412 ± 281 days). AI increased by 4% (1-6%) per month of support (p < 0.01). AI-positive patients were older at implant (weighted mean difference, 7.7 [4.3; 11.1]; p < 0.01). Female sex (0.002 ± 0.001; p = 0.01) and smaller body surface area (-0.003 ± 0.001 per m; p < 0.01) correlated with progressive AI. Destination therapy patients (odds ratio [OR], 5.3 [1.2, 24]; p = 0.02) and those with Cf-LVAD pumps were likely to develop AI (hazard ratio [HR], 2.2 [1.2, 3.8]; p < 0.01). A closed aortic valve was associated with AI (OR, 4.7 [1.9, 11.8]; p < 0.01). Survival was comparable in both cohorts (HR, 1.5 [0.81, 2.8]; p = 0.2). A significant number of patients develop de novo AI during LVAD support. Advanced age, longer support duration, continuous-flow pumps, and a closed aortic valve are associated with AI. Large cohort studies would improve our understanding of this condition.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalASAIO Journal
Volume60
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Meta-Analysis
Aortic Valve
Hazards
Odds Ratio
Pumps
Body Surface Area
Incidence
MEDLINE
Observational Studies
Cohort Studies
Equipment and Supplies
Survival

Keywords

  • Aortic insufficiency
  • Congestive heart failure
  • Left ventricular assist device

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

De novo aortic insufficiency during long-term support on a left ventricular assist device : A systematic review and meta-analysis. / Deo, Salil V.; Sharma, Vikas; Cho, Yang Hyun; Shah, Ishan K.; Park, Soon J.

In: ASAIO Journal, Vol. 60, No. 2, 2014, p. 183-188.

Research output: Contribution to journalArticle

Deo, Salil V. ; Sharma, Vikas ; Cho, Yang Hyun ; Shah, Ishan K. ; Park, Soon J. / De novo aortic insufficiency during long-term support on a left ventricular assist device : A systematic review and meta-analysis. In: ASAIO Journal. 2014 ; Vol. 60, No. 2. pp. 183-188.
@article{ce7cba87ea1a406d9724c143cb401476,
title = "De novo aortic insufficiency during long-term support on a left ventricular assist device: A systematic review and meta-analysis",
abstract = "Aortic insufficiency (AI) may occur while supported on a left ventricular assist device (LVAD). We conducted a systematic review to determine the incidence, predictors, and consequences of AI during LVAD support. MEDLINE was searched for original studies presenting clinical data regarding patients who developed AI during LVAD implant. Seven observational studies (657 patients) were selected for review; 65{\%} of patients underwent implantation with a continuous-flow device (Cf-LVAD). The incidence of AI was 25{\%} (11-42{\%}) (Support period: 412 ± 281 days). AI increased by 4{\%} (1-6{\%}) per month of support (p < 0.01). AI-positive patients were older at implant (weighted mean difference, 7.7 [4.3; 11.1]; p < 0.01). Female sex (0.002 ± 0.001; p = 0.01) and smaller body surface area (-0.003 ± 0.001 per m; p < 0.01) correlated with progressive AI. Destination therapy patients (odds ratio [OR], 5.3 [1.2, 24]; p = 0.02) and those with Cf-LVAD pumps were likely to develop AI (hazard ratio [HR], 2.2 [1.2, 3.8]; p < 0.01). A closed aortic valve was associated with AI (OR, 4.7 [1.9, 11.8]; p < 0.01). Survival was comparable in both cohorts (HR, 1.5 [0.81, 2.8]; p = 0.2). A significant number of patients develop de novo AI during LVAD support. Advanced age, longer support duration, continuous-flow pumps, and a closed aortic valve are associated with AI. Large cohort studies would improve our understanding of this condition.",
keywords = "Aortic insufficiency, Congestive heart failure, Left ventricular assist device",
author = "Deo, {Salil V.} and Vikas Sharma and Cho, {Yang Hyun} and Shah, {Ishan K.} and Park, {Soon J.}",
year = "2014",
doi = "10.1097/MAT.0000000000000042",
language = "English (US)",
volume = "60",
pages = "183--188",
journal = "ASAIO Journal",
issn = "0162-1432",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - De novo aortic insufficiency during long-term support on a left ventricular assist device

T2 - A systematic review and meta-analysis

AU - Deo, Salil V.

AU - Sharma, Vikas

AU - Cho, Yang Hyun

AU - Shah, Ishan K.

AU - Park, Soon J.

PY - 2014

Y1 - 2014

N2 - Aortic insufficiency (AI) may occur while supported on a left ventricular assist device (LVAD). We conducted a systematic review to determine the incidence, predictors, and consequences of AI during LVAD support. MEDLINE was searched for original studies presenting clinical data regarding patients who developed AI during LVAD implant. Seven observational studies (657 patients) were selected for review; 65% of patients underwent implantation with a continuous-flow device (Cf-LVAD). The incidence of AI was 25% (11-42%) (Support period: 412 ± 281 days). AI increased by 4% (1-6%) per month of support (p < 0.01). AI-positive patients were older at implant (weighted mean difference, 7.7 [4.3; 11.1]; p < 0.01). Female sex (0.002 ± 0.001; p = 0.01) and smaller body surface area (-0.003 ± 0.001 per m; p < 0.01) correlated with progressive AI. Destination therapy patients (odds ratio [OR], 5.3 [1.2, 24]; p = 0.02) and those with Cf-LVAD pumps were likely to develop AI (hazard ratio [HR], 2.2 [1.2, 3.8]; p < 0.01). A closed aortic valve was associated with AI (OR, 4.7 [1.9, 11.8]; p < 0.01). Survival was comparable in both cohorts (HR, 1.5 [0.81, 2.8]; p = 0.2). A significant number of patients develop de novo AI during LVAD support. Advanced age, longer support duration, continuous-flow pumps, and a closed aortic valve are associated with AI. Large cohort studies would improve our understanding of this condition.

AB - Aortic insufficiency (AI) may occur while supported on a left ventricular assist device (LVAD). We conducted a systematic review to determine the incidence, predictors, and consequences of AI during LVAD support. MEDLINE was searched for original studies presenting clinical data regarding patients who developed AI during LVAD implant. Seven observational studies (657 patients) were selected for review; 65% of patients underwent implantation with a continuous-flow device (Cf-LVAD). The incidence of AI was 25% (11-42%) (Support period: 412 ± 281 days). AI increased by 4% (1-6%) per month of support (p < 0.01). AI-positive patients were older at implant (weighted mean difference, 7.7 [4.3; 11.1]; p < 0.01). Female sex (0.002 ± 0.001; p = 0.01) and smaller body surface area (-0.003 ± 0.001 per m; p < 0.01) correlated with progressive AI. Destination therapy patients (odds ratio [OR], 5.3 [1.2, 24]; p = 0.02) and those with Cf-LVAD pumps were likely to develop AI (hazard ratio [HR], 2.2 [1.2, 3.8]; p < 0.01). A closed aortic valve was associated with AI (OR, 4.7 [1.9, 11.8]; p < 0.01). Survival was comparable in both cohorts (HR, 1.5 [0.81, 2.8]; p = 0.2). A significant number of patients develop de novo AI during LVAD support. Advanced age, longer support duration, continuous-flow pumps, and a closed aortic valve are associated with AI. Large cohort studies would improve our understanding of this condition.

KW - Aortic insufficiency

KW - Congestive heart failure

KW - Left ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84896402910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896402910&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000042

DO - 10.1097/MAT.0000000000000042

M3 - Article

C2 - 24399060

AN - SCOPUS:84896402910

VL - 60

SP - 183

EP - 188

JO - ASAIO Journal

JF - ASAIO Journal

SN - 0162-1432

IS - 2

ER -